A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion Combination with Bevacizumab (Bev) versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
|Effective start/end date||6/1/17 → 7/31/22|
- BOSTON BIOMEDICAL, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.